PMID- 23011868
OWN - NLM
STAT- MEDLINE
DCOM- 20130919
LR  - 20211021
IS  - 2325-9574 (Print)
IS  - 2325-9582 (Electronic)
IS  - 2325-9574 (Linking)
VI  - 12
IP  - 1
DP  - 2013 Jan-Feb
TI  - Clinical outcomes among HIV/tuberculosis-coinfected patients developing immune 
      reconstitution inflammatory syndrome after HAART initiation in South India.
PG  - 28-31
LID - 10.1177/1545109712457711 [doi]
AB  - INTRODUCTION: We determine the frequency and immunological outcome of developing 
      immune reconstitution inflammatory syndrome (IRIS) among HIV/tuberculosis 
      (TB)-coinfected Indians receiving highly active antiretroviral therapy (HAART). 
      METHODS: Patients coinfected with TB and HIV who initiated HAART were classified 
      based on treatment outcomes (IRIS and non-IRIS) utilizing an observational 
      HIV/AIDS cohort. RESULTS: A total of 1731 HIV/TB-coinfected patients initiated 
      HAART, and 95 of these patients (5.5%) developed TB-IRIS, with an incidence rate 
      of 0.26 per 100 person-years. Patients who developed IRIS had significantly 
      higher CD4 counts than non-IRIS patients at the time of initiating HAART, as well 
      as after 6 months, 18 months, and 24 months following HAART initiation (P < .05). 
      CONCLUSIONS: HIV/TB-coinfected patients who developed IRIS following HAART 
      initiation had equivalent clinical outcomes compared with their HIV/TB-coinfected 
      counterparts who did not develop IRIS, suggesting minimal long-term risks 
      associated with IRIS.
FAU - Kumarasamy, N
AU  - Kumarasamy N
AD  - YRG Centre for AIDS Research and Education, Voluntary Health Services (VHS), 
      Chennai, India. kumarasamy@yrgcare.org
FAU - Venkatesh, Kartik K
AU  - Venkatesh KK
FAU - Vignesh, R
AU  - Vignesh R
FAU - Devaleenal, B
AU  - Devaleenal B
FAU - Poongulali, S
AU  - Poongulali S
FAU - Yepthomi, Tokuga
AU  - Yepthomi T
FAU - Flanigan, Timothy P
AU  - Flanigan TP
FAU - Benson, Constance
AU  - Benson C
FAU - Mayer, Kenneth H
AU  - Mayer KH
LA  - eng
GR  - D43 TW000237/TW/FIC NIH HHS/United States
GR  - U01 AI069432/AI/NIAID NIH HHS/United States
GR  - U01AI069432/AI/NIAID NIH HHS/United States
GR  - D43TW00237/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20120924
PL  - United States
TA  - J Int Assoc Provid AIDS Care
JT  - Journal of the International Association of Providers of AIDS Care
JID - 101603896
SB  - IM
MH  - Adult
MH  - *Antiretroviral Therapy, Highly Active
MH  - CD4 Lymphocyte Count
MH  - Female
MH  - HIV Infections/*drug therapy/*epidemiology
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/diagnosis/*epidemiology
MH  - Incidence
MH  - India/epidemiology
MH  - Male
MH  - Tuberculosis/*epidemiology
PMC - PMC5578704
MID - NIHMS899998
COIS- Declaration of Conflicting Interests The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2012/09/27 06:00
MHDA- 2013/09/21 06:00
PMCR- 2017/08/31
CRDT- 2012/09/27 06:00
PHST- 2012/09/27 06:00 [entrez]
PHST- 2012/09/27 06:00 [pubmed]
PHST- 2013/09/21 06:00 [medline]
PHST- 2017/08/31 00:00 [pmc-release]
AID - 1545109712457711 [pii]
AID - 10.1177/1545109712457711 [doi]
PST - ppublish
SO  - J Int Assoc Provid AIDS Care. 2013 Jan-Feb;12(1):28-31. doi: 
      10.1177/1545109712457711. Epub 2012 Sep 24.